MedTrace Logo

Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion

NCT01670786 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-05-13

No results posted yet for this study

Summary

Iodopovidone is safe when using as a pleurodesis sclerosing agent for malignant pleural effusion, with minimal adverse events, especially reducing dose.

Conditions

  • Pleural Effusion, Malignant

Interventions

PROCEDURE

pleurodesis

Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion

Sponsors & Collaborators

  • Instituto do Coracao

    collaborator OTHER_GOV

  • Instituto do Cancer do Estado de São Paulo

    collaborator OTHER

  • Grupo de Pesquisa em Pleura e Oncologia Toracica

    lead NETWORK

Principal Investigators

  • Ricardo M Terra, MD, PhD · InCor Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01670786 on ClinicalTrials.gov